

**Worldwide Sales****\$2.8B****9%** Reported Basis**4%** Operational Basis¹**2Q Adjusted Earnings Per Share¹ (EPS) \$0.77 ↑ 22%****Raised Outlook for Full-Year Adjusted EPS² \$2.94 - \$3.00**

"Our solid second quarter performance supports the strategic priorities we laid out at our May investor conference to deliver sustainable long-term growth across our diversified portfolio. We remain relentlessly focused on enhancing operational efficiency throughout the company, while also increasing investments in innovative therapies and products to benefit patients and healthcare providers and accelerate top-line growth."

José (Joe) E. Almeida
Chairman and Chief Executive Officer

¹ Visit www.baxter.com for information regarding non-GAAP financial metrics used here, including operational sales and adjusted earnings per share.

² Versus previous guidance of \$2.85 - \$2.93 issued on April 26, 2018.